Disclaimer: Not investment advice. Do your own research. For informational purposes only. I reserve the right to change positions after publishing as events change. Position rankings accurate as of 1/31/24. Last time I sent an email it was on 1/1/24: “My Favorite Biotech Ideas For 2024” and I listed 12 public companies that I was focused on for the new year. After a month of reflection and news flow, I have been making some tweaks.
Hi Matt, thank you for your post and sharing your insights--very enlightening and informative. I am long 6/10 from your current top 10.
As for CHRS, I was surprised at the Cimerli divestment as well, but I'm not sure it was such a terrible idea.
Including the ones already approved, I believe there are around 10 ranibizumab biosimilars in development. I don't know how long Cimerli could have continued its current growth trajectory while maintaing favorable margins. Add to that several new promising drugs currently in development for the same indications.
Yusimry economics are different, though I wouldn't be surprised if they eventually divest Yusimry as well. As for Udenyca, since it overlaps with their growing oncology franchise--I think it might make more sense from a strategic viewpoint.
I think the generics/biosimilar business is tough unless one can operate at scale and leverage the sales org across multiple assets. The Cimerli deal helps them start to rightsize the balance sheet--while continuing to grow higher margin revenue to replace revenue lost from Cimerli. Anyway, jmtc.
Hi Matt,
Phathom Pharma (PHAT) is taking on 320 sales staff to promote Voquezna this year:
https://investors.phathompharma.com/static-files/05e1d7fe-b638-488b-b01a-88764b862d10
They claim to have enough funds for operations until 2026.
Was wondering if there is a more efficient method to reach health care professionals other than having this huge salesforce?
Hi Matt, thank you for your post and sharing your insights--very enlightening and informative. I am long 6/10 from your current top 10.
As for CHRS, I was surprised at the Cimerli divestment as well, but I'm not sure it was such a terrible idea.
Including the ones already approved, I believe there are around 10 ranibizumab biosimilars in development. I don't know how long Cimerli could have continued its current growth trajectory while maintaing favorable margins. Add to that several new promising drugs currently in development for the same indications.
Yusimry economics are different, though I wouldn't be surprised if they eventually divest Yusimry as well. As for Udenyca, since it overlaps with their growing oncology franchise--I think it might make more sense from a strategic viewpoint.
I think the generics/biosimilar business is tough unless one can operate at scale and leverage the sales org across multiple assets. The Cimerli deal helps them start to rightsize the balance sheet--while continuing to grow higher margin revenue to replace revenue lost from Cimerli. Anyway, jmtc.